3.連結財務諸表及び主な注記
(1)連結貸借対照表
| | |
| | (単位:百万円) |
| 前連結会計年度 (2020年3月31日) | 当連結会計年度 (2021年3月31日) |
資産の部 | | |
流動資産 | | |
現金及び預金 | 10,973 | 26,260 |
受取手形及び売掛金 | 7,977 | 8,183 |
有価証券 | 220 | - |
商品及び製品 | 880 | 1,367 |
仕掛品 | 2,929 | 3,538 |
原材料及び貯蔵品 | 5,046 | 8,649 |
その他 | 315 | 546 |
流動資産合計 | 28,342 | 48,545 |
固定資産 | | |
有形固定資産 | | |
建物及び構築物(純額) | 5,115 | 6,295 |
機械装置及び運搬具(純額) | 867 | 1,282 |
土地 | 5,664 | 7,663 |
建設仮勘定 | 2,283 | 841 |
その他(純額) | 944 | 1,088 |
有形固定資産合計 | 14,875 | 17,172 |
無形固定資産 | | |
特許権 | - | 2,988 |
その他 | 263 | 244 |
無形固定資産合計 | 263 | 3,232 |
投資その他の資産 | | |
投資有価証券 | 2,408 | 2,572 |
繰延税金資産 | 721 | 1,739 |
退職給付に係る資産 | 243 | 225 |
その他 | 943 | 300 |
貸倒引当金 | △23 | △4 |
投資その他の資産合計 | 4,294 | 4,833 |
固定資産合計 | 19,433 | 25,238 |
資産合計 | 47,775 | 73,784 |
| | |
| | (単位:百万円) |
| 前連結会計年度 (2020年3月31日) | 当連結会計年度 (2021年3月31日) |
負債の部 | | |
流動負債 | | |
支払手形及び買掛金 | 679 | 2,932 |
短期借入金 | 4,880 | 12,850 |
未払法人税等 | 534 | 2,646 |
圧縮未決算特別勘定 | - | 3,828 |
賞与引当金 | 713 | 850 |
役員賞与引当金 | 77 | 63 |
その他 | 3,549 | 5,855 |
流動負債合計 | 10,434 | 29,028 |
固定負債 | | |
社債 | - | 500 |
長期借入金 | 3,800 | 4,750 |
債務保証損失引当金 | 108 | - |
従業員株式給付引当金 | 47 | 62 |
退職給付に係る負債 | 730 | 798 |
その他 | 75 | 88 |
固定負債合計 | 4,761 | 6,199 |
負債合計 | 15,195 | 35,227 |
純資産の部 | | |
株主資本 | | |
資本金 | 9,061 | 9,061 |
資本剰余金 | 10,891 | 10,941 |
利益剰余金 | 15,039 | 20,904 |
自己株式 | △3,865 | △3,685 |
株主資本合計 | 31,127 | 37,222 |
その他の包括利益累計額 | | |
その他有価証券評価差額金 | 583 | 691 |
繰延ヘッジ損益 | - | 0 |
為替換算調整勘定 | 134 | △18 |
退職給付に係る調整累計額 | △39 | △31 |
その他の包括利益累計額合計 | 679 | 641 |
新株予約権 | 584 | 517 |
非支配株主持分 | 189 | 174 |
純資産合計 | 32,579 | 38,557 |
負債純資産合計 | 47,775 | 73,784 |
E0097345520JCRファーマ株式会社JCR Pharmaceuticals Co.,Ltd.通期第1号参考様式 [日本基準](連結)Japan GAAPtrueCTECTE2020-04-012021-03-31FY2021-03-312019-04-012020-03-312020-03-311falsefalsefalse455202019-04-012020-03-31jppfs_cor:ValuationDifferenceOnAvailableForSaleSecuritiesMember455202019-04-012020-03-31jppfs_cor:ShareholdersEquityMember455202019-04-012020-03-31jppfs_cor:TreasuryStockMember455202019-04-012020-03-31jppfs_cor:RetainedEarningsMember455202019-04-012020-03-31jppfs_cor:CapitalSurplusMember455202021-05-13455202021-03-31455202020-04-012021-03-31455202020-03-31455202019-04-012020-03-31455202019-03-31455202021-03-31jppfs_cor:ValuationAndTranslationAdjustmentsMember455202021-03-31jppfs_cor:RemeasurementsOfDefinedBenefitPlansMember455202021-03-31jppfs_cor:ForeignCurrencyTranslationAdjustmentMember455202021-03-31jppfs_cor:DeferredGainsOrLossesOnHedgesMember455202021-03-31jppfs_cor:ValuationDifferenceOnAvailableForSaleSecuritiesMember455202021-03-31jppfs_cor:ShareholdersEquityMember455202021-03-31jppfs_cor:TreasuryStockMember455202019-04-012020-03-31jppfs_cor:CapitalStockMember455202019-03-31jppfs_cor:NonControllingInterestsMember455202019-03-31jppfs_cor:SubscriptionRightsToSharesMember455202019-03-31jppfs_cor:ValuationAndTranslationAdjustmentsMember455202019-03-31jppfs_cor:RemeasurementsOfDefinedBenefitPlansMember455202019-03-31jppfs_cor:ForeignCurrencyTranslationAdjustmentMember455202019-03-31jppfs_cor:DeferredGainsOrLossesOnHedgesMember455202019-03-31jppfs_cor:ValuationDifferenceOnAvailableForSaleSecuritiesMember455202019-03-31jppfs_cor:ShareholdersEquityMember455202019-03-31jppfs_cor:TreasuryStockMember455202019-03-31jppfs_cor:RetainedEarningsMember455202019-03-31jppfs_cor:CapitalSurplusMember455202019-03-31jppfs_cor:CapitalStockMember455202021-03-31jppfs_cor:RetainedEarningsMember455202020-04-012021-03-31jppfs_cor:RemeasurementsOfDefinedBenefitPlansMember455202020-04-012021-03-31jppfs_cor:ForeignCurrencyTranslationAdjustmentMember455202020-04-012021-03-31jppfs_cor:DeferredGainsOrLossesOnHedgesMember455202020-04-012021-03-31jppfs_cor:ValuationDifferenceOnAvailableForSaleSecuritiesMember455202020-04-012021-03-31jppfs_cor:ShareholdersEquityMember455202020-04-012021-03-31jppfs_cor:TreasuryStockMember455202020-04-012021-03-31jppfs_cor:RetainedEarningsMember455202020-04-012021-03-31jppfs_cor:CapitalSurplusMember455202020-04-012021-03-31jppfs_cor:CapitalStockMember455202020-03-31jppfs_cor:SubscriptionRightsToSharesMember455202020-03-31jppfs_cor:ValuationAndTranslationAdjustmentsMember455202020-03-31jppfs_cor:RemeasurementsOfDefinedBenefitPlansMember455202020-03-31jppfs_cor:ForeignCurrencyTranslationAdjustmentMember455202020-03-31jppfs_cor:DeferredGainsOrLossesOnHedgesMember455202020-03-31jppfs_cor:ValuationDifferenceOnAvailableForSaleSecuritiesMember455202020-03-31jppfs_cor:ShareholdersEquityMember455202020-03-31jppfs_cor:TreasuryStockMember455202020-03-31jppfs_cor:RetainedEarningsMember455202020-03-31jppfs_cor:CapitalSurplusMember455202020-03-31jppfs_cor:CapitalStockMember455202019-04-012020-03-31jppfs_cor:NonControllingInterestsMember455202019-04-012020-03-31jppfs_cor:SubscriptionRightsToSharesMember455202019-04-012020-03-31jppfs_cor:ValuationAndTranslationAdjustmentsMember455202019-04-012020-03-31jppfs_cor:RemeasurementsOfDefinedBenefitPlansMember455202019-04-012020-03-31jppfs_cor:ForeignCurrencyTranslationAdjustmentMember455202021-03-31jppfs_cor:CapitalSurplusMember455202021-03-31jppfs_cor:CapitalStockMember455202020-04-012021-03-31jppfs_cor:NonControllingInterestsMember455202020-04-012021-03-31jppfs_cor:SubscriptionRightsToSharesMember455202020-04-012021-03-31jppfs_cor:ValuationAndTranslationAdjustmentsMember455202020-03-31jppfs_cor:NonControllingInterestsMember455202021-03-31jppfs_cor:NonControllingInterestsMember455202021-03-31jppfs_cor:SubscriptionRightsToSharesMemberxbrli:pureiso4217:JPY